Insights
Insights From Our Experts
Articles
Navigating the New EU HTA Landscape: Pamela Vo on Strategic Evidence Planning
In a recent pharmaphorum interview, EVERSANA’s Pamela Vo emphasized the importance of early strategic evidence planning under the EU’s new Health Technology Assessment Regulation (HTAR). With the Joint Clinical Assessment (JCA) streamlining clinical evaluations across member…
Redefining Field Deployment – Bridging “Share of Voice” with “Share of Influence” for Lasting Impact
In a pharmaceutical environment where promotional noise is louder than ever, there’s a strategic blueprint for cutting through the clutter to create meaningful impact and establish long-lasting brand loyalty among healthcare stakeholders. Sales representatives and television…
“Nothing changes if nothing changes.”
“Nothing changes if nothing changes.” Why an integrated commercialization platform with the amplified power of a direct-to-patient (DTP) channel is no longer an option. It’s a must. Two-thirds of drug launches fall short of revenue goals,…
EVERSANA & Google Cloud Bring AI Agency Concept to Life
EVERSANA is redefining the future of medical marketing with the launch of its groundbreaking AI Agency—an end-to-end solution developed in partnership with Google Cloud. This platform, unveiled at Google’s New York office recently, promises to deliver…
Evaluation of HTA Frameworks for In Vivo Diagnostics: Assessing Methodological Gaps and Implications for Market Access
Health technology assessments (HTAs) are crucial for market access and reimbursement of diagnostic innovations, yet current frameworks often fail to reflect the true value of in vivo diagnostics—such as molecular imaging (MI) tracers and contrast media…
Optimizing Product Commercialization in Today’s IDN Environment
Traditional sales models that rely solely on prescriber outreach or consumer advertising are no longer effective. With nearly 70% of U.S. physicians employed by Integrated Delivery Networks (IDNs), the way therapies are evaluated, approved, and accessed…
Navigating MFN: Alan Crowther on What Pharma Brands Must Know Now
As the pharmaceutical industry grapples with the implications of the Most Favored Nation (MFN) Executive Order, Alan Crowther, General Manager of Global Pricing & Market Access Solutions, offers timely insights into what this directive means for…
Redefining CAR-T Access: Strategic Implications of the FDA’s REMS Decision
The FDA’s removal of REMS requirements for BCMA- and CD19-directed CAR-T therapies marks a pivotal regulatory milestone—reducing administrative burdens and opening the door to broader patient access. But the real opportunity lies in how manufacturers respond…
Repairing the Patient Journey: How Pharma Can Fix the Obvious – and Not So Obvious – Breaking Points of Nonadherence
When nearly half of all treatment failures stem from nonadherence, the stakes for patients, and for pharma, could not be higher. One of the most persistent barriers in healthcare, leading to preventable hospitalizations, lost lives and…
Treatment Effect Modifiers and Prognostic Factors in Multiple Myeloma: Enabling Smarter Trials and Comparative Research
Multiple myeloma (MM) remains a complex and incurable hematologic malignancy, despite the rapid evolution of therapeutic options over the past decade. With the emergence of novel drug classes—ranging from monoclonal antibody-drug conjugates to CAR-T cell therapies—the…